Literature DB >> 25917364

Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream.

Helga Sertić Milić1, Ana Franjević, Gordana Bubanović, Ante Marušić, Igor Nikolić, Igor Puljić.   

Abstract

BACKGROUND: The computed tomography (CT) is the "golden standard" for the assessment of lung cancer progression due to its ability to clearly display the radiomorphologic characteristics. As lung cancer mortality is very high, more comprehensive approaches may be needed for its earlier diagnosis. The research hypothesis was to investigate the relation between the CT morphologic characteristics (size, stage, and edges) of pulmonary lesion and the extent of release of a soluble fragment of cytokeratin 19 being a part of the cytoskeleton of lung epithelial cells.
METHODS: This is a retrospective study including 246 pulmonary lesions being diagnosed and subsequently treated at the University Hospital Centre Zagreb, Croatia. The information about the relevant clinical, radiological, and laboratory facts was collected at the time of diagnosis in 164 NSCLC patients, 52 patients with pulmonary metastases, and 30 benign cysts. CYFRA 21-1 was determined by electrochemiluminescence immunoassay. The nonparametric statistical methods were applied.
RESULTS: There was a positive correlation between the size and CYFRA 21-1 in NSCLC unlike metastases or cysts (p = 0.0001). The highest values of CYFRA 21-1 were seen in advanced stages of NSCLC and lesions with spiculated edges.
CONCLUSIONS: The level of CYFRA 21-1 positively correlates with the greatest size of NSCLC measured by CT. The differences in CYFRA 21-1 according to TNM classification are significant (p = 0.0001): higher values were observed in advanced stages and with tumors having spiculated, lobulated, and poorly defined edges. The combination of CYFRA 21-1 and CT may help articulate the malignancy of pulmonary lesions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25917364     DOI: 10.1007/s00508-014-0678-2

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  19 in total

Review 1.  Computed tomography in staging for lung cancer.

Authors:  J A Verschakelen; J Bogaert; W De Wever
Journal:  Eur Respir J Suppl       Date:  2002-02

2.  Multicenter analysis of survival and prognostic factors in pathologic stage I non-small-cell lung cancer according to the new 2009 TNM classification.

Authors:  Pablo León-Atance; Nicolás Moreno-Mata; Federico González-Aragoneses; Miguel Ángel Cañizares-Carretero; María Dolores García-Jiménez; Marta Genovés-Crespo; Antonio Francisco Honguero-Martínez; Carlos Alberto Rombolá; Carlos María Simón-Adiego; Rafael Peñalver-Pascual
Journal:  Arch Bronconeumol       Date:  2011-06-14       Impact factor: 4.872

3.  Local extension at the hilum region is associated with worse long-term survival in stage I non-small cell lung cancers.

Authors:  Chang Chen; Fang Bao; Hui Zheng; Yi-ming Zhou; Min-wei Bao; Hui-kang Xie; Ge-ning Jiang; Jia-an Ding; Wen Gao
Journal:  Ann Thorac Surg       Date:  2011-12-27       Impact factor: 4.330

Review 4.  Diagnosis and staging of lung cancer.

Authors:  J D Hyer; G Silvestri
Journal:  Clin Chest Med       Date:  2000-03       Impact factor: 2.878

5.  Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.

Authors:  J L Pujol; J M Boher; J Grenier; X Quantin
Journal:  Lung Cancer       Date:  2001 Feb-Mar       Impact factor: 5.705

6.  The relationship of clinical findings to CT scan evidence of adrenal gland metastases in the staging of bronchogenic carcinoma.

Authors:  G A Silvestri; J E Lenz; S N Harper; R A Morse; G L Colice
Journal:  Chest       Date:  1992-12       Impact factor: 9.410

Review 7.  Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

Authors:  Eric M Toloza; Linda Harpole; Douglas C McCrory
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

Review 8.  New imaging techniques in the treatment guidelines for lung cancer.

Authors:  C Schaefer-Prokop; M Prokop
Journal:  Eur Respir J Suppl       Date:  2002-02

9.  The prognostic factors of resected non-small cell lung cancer with chest wall invasion.

Authors:  Chang Young Lee; Chun Sung Byun; Jin Gu Lee; Dae Joon Kim; Byoung Chul Cho; Kyung Young Chung; In Kyu Park
Journal:  World J Surg Oncol       Date:  2012-01-12       Impact factor: 2.754

Review 10.  The human keratins: biology and pathology.

Authors:  Roland Moll; Markus Divo; Lutz Langbein
Journal:  Histochem Cell Biol       Date:  2008-05-07       Impact factor: 4.304

View more
  4 in total

1.  Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis.

Authors:  Takeshi Numata; Takeo Endo; Hidetoshi Yanai; Kyoko Ota; Yusuke Yamamoto; Kei Shimizu; Hideyasu Yamada; Kenji Hayashihara; Shinichiro Okauchi; Hiroaki Satoh; Yutaka Yamada; Tomohiro Tamura; Kazuto Saito; Norihiro Kikuchi; Koichi Kurishima; Hiroichi Ishikawa; Hiroko Watanabe; Toshihiro Shiozawa; Nobuyuki Hizawa; Yasunori Funayama; Shigen Hayashi; Hiroyuki Nakamura; Takaaki Yamashita
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis.

Authors:  Guoqiao Zhang; Rong Zeng; Kai Wang; Yinzhuoyang A; Linhai Li; Kunmei Gong
Journal:  Oncol Lett       Date:  2019-01-04       Impact factor: 2.967

3.  The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.

Authors:  M G Dal Bello; R A Filiberti; A Alama; A M Orengo; M Mussap; S Coco; I Vanni; S Boccardo; E Rijavec; C Genova; F Biello; G Barletta; G Rossi; M Tagliamento; C Maggioni; F Grossi
Journal:  J Transl Med       Date:  2019-03-08       Impact factor: 5.531

4.  Prognostic nomogram on clinicopathologic features and serum indicators for advanced non-small cell lung cancer patients treated with anti-PD-1 inhibitors.

Authors:  Rong Chai; Yinxing Fan; Jiayi Zhao; Fan He; Jianong Li; Yiping Han
Journal:  Ann Transl Med       Date:  2020-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.